Publication: Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with $\textit{BRAF}$V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with $\textit{BRAF}$V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Date
Date
Date
Citations
Tawbi, H. A., Robert, C., Brase, J. C., Gusenleitner, D., Gasal, E., Garrett, J., Savchenko, A., Görgün, G., Flaherty, K. T., Ribas, A., Dummer, R., Schadendorf, D., Long, G. V., Nathan, P. D., & Ascierto, P. A. (2022). Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with $\textit{BRAF}$V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Journal for ImmunoTherapy of Cancer, 10(6), e004226. https://doi.org/10.1136/jitc-2021-004226
Abstract
Abstract
Abstract
BackgroundThe randomized phase 3 COMBI-i trial did not meet its primary endpoint of improved progression-free survival (PFS) with spartalizumab plus dabrafenib and trametinib (sparta-DabTram) vs placebo plus dabrafenib and trametinib (placebo-DabTram) in the overall population of patients with unresectable/metastatic $\textit{BRAF}$
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Tawbi, Hussein A
- Robert, Caroline
- Brase, Jan C
- Gusenleitner, Daniel
- Gasal, Eduard
- Garrett, James
- Savchenko, Alexander
- Görgün, Güllü
- Flaherty, Keith T
- Ribas, Antoni
- Dummer, Reinhard
- Schadendorf, Dirk
- Long, Georgina V
- Nathan, Paul D
- Ascierto, Paolo A
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Tawbi, H. A., Robert, C., Brase, J. C., Gusenleitner, D., Gasal, E., Garrett, J., Savchenko, A., Görgün, G., Flaherty, K. T., Ribas, A., Dummer, R., Schadendorf, D., Long, G. V., Nathan, P. D., & Ascierto, P. A. (2022). Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with $\textit{BRAF}$V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). Journal for ImmunoTherapy of Cancer, 10(6), e004226. https://doi.org/10.1136/jitc-2021-004226
